Delivery of beta-blockers through an inhalation route
First Claim
1. A method of treating hypertension, acute myocardial infarction, cardiac arrhythmias or side effects of situational anxiety in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation,wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol and metoprolol, andwherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a method aspect of the present invention, atenolol, pindolol, esmolol, propranolol, or metoprolol is administered to a patient through an inhalation route. The method comprises: a) heating a composition of atenolol, pindolol, esmolol, propranolol, or metoprolol, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route is provided which comprises: a) a thin coating of an atenolol, pindolol, esmolol, propranolol, or metoprolol composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
40 Claims
-
1. A method of treating hypertension, acute myocardial infarction, cardiac arrhythmias or side effects of situational anxiety in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation,
wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol and metoprolol, and wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
-
11. A method of administering a drug condensation aerosol to a patient comprising administering the drug condensation aerosol to the patient by inhalation,
wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol and metoprolol, and wherein the drug condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
-
12. A kit for delivering a drug condensation aerosol comprising:
-
a. a thin layer containing the drug, on a solid support, wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol and metoprolol, and b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
Specification